Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BICO Group: Invitation to presentation of BICO's Q1 results 2022

BICO Group

Following the release of the report, combined presentation audiocasts and telephone conferences with the opportunity to ask questions will be held in English at 09:00 CEST and 16:00 CEST on the same day, with CEO Erik Gatenholm, CTO Hector Martinez, Interim CFO Mikael Engblom presenting the report.

The presentation audiocasts will be accessible via the following links:

Morning audiocast, at 09:00 CEST:

https://tv.streamfabriken.com/bico-q1-2022-am

To participate via telephone, please call any of the following numbers:

SE: +46 856 642 703

UK: +44 3333 009 034

US: +1 631 91 314 226

PIN for US: 46659360#

Afternoon audiocast, at 16:00 CEST:

https://tv.streamfabriken.com/bico-q1-2022-pm

To participate via telephone, please call any of the following numbers:

SE: + 46 850 558 352

UK: +44 3333 009 264

US: +1 6319 131 422

PIN for US: 36222967#

The presentation will also be available on the company's website: https://bico.com/investors/financials/

For further information, please contact:

Åsa Hillsten, SVP Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on May 11, 2022, at 07:00 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.